{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T20:48:55Z","timestamp":1769719735632,"version":"3.49.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Health Institutes of T\u00fcrkiye","award":["2022-B-01-14333)"],"award-info":[{"award-number":["2022-B-01-14333)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-025-02594-1","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:46:43Z","timestamp":1766051203000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Menin-driven mTOR signaling sustains taxane resistance in CRPC and reveals a targetable vulnerability for combination therapy"],"prefix":"10.1186","volume":"24","author":[{"given":"Ipek","family":"Bulut","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Buse","family":"Cevatemre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neslihan","family":"Yuksel-Catal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamzah","family":"Syed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamer","family":"Onder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ceyda","family":"Acilan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"issue":"3","key":"2594_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"2594_CR2","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/pro6.1129","volume":"5","author":"G Li","year":"2021","unstructured":"Li G, et al. Guidelines for radiotherapy of prostate cancer (2020 edition). Precision Radiation Oncol. 2021;5(3):160\u201382.","journal-title":"Precision Radiation Oncol"},{"key":"2594_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1464-410X.2012.11215.x","volume":"109","author":"F Schroder","year":"2012","unstructured":"Schroder F, et al. Androgen deprivation therapy: past, present and future. BJU Int. 2012;109:1\u201312.","journal-title":"BJU Int"},{"issue":"5\u20136","key":"2594_CR4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1053\/j.seminoncol.2018.10.001","volume":"45","author":"G Ingrosso","year":"2018","unstructured":"Ingrosso G, et al. Current therapeutic options in metastatic castration-resistant prostate cancer. Semin Oncol. 2018;45(5\u20136):303\u201315.","journal-title":"Semin Oncol"},{"issue":"2","key":"2594_CR5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.urolonc.2013.01.005","volume":"32","author":"F Saad","year":"2014","unstructured":"Saad F, Miller K. Treatment options in castration-resistant prostate cancer: current therapies and emerging docetaxel-based regimens. Urol Oncol. 2014;32(2):70\u20139.","journal-title":"Urol Oncol"},{"issue":"2","key":"2594_CR6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41419-024-06422-1","volume":"15","author":"B Cevatemre","year":"2024","unstructured":"Cevatemre B, et al. Exploiting epigenetic targets to overcome taxane resistance in prostate cancer. Cell Death Dis. 2024;15(2):132.","journal-title":"Cell Death Dis"},{"issue":"27","key":"2594_CR7","doi-asserted-by":"publisher","first-page":"17118","DOI":"10.1074\/jbc.272.27.17118","volume":"272","author":"P Giannakakou","year":"1997","unstructured":"Giannakakou P, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem. 1997;272(27):17118\u201325.","journal-title":"J Biol Chem"},{"issue":"3","key":"2594_CR8","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00280-019-03905-3","volume":"84","author":"M van Eijk","year":"2019","unstructured":"van Eijk M, et al. Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes. Cancer Chemother Pharmacol. 2019;84(3):487\u201399.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"2594_CR9","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.3892\/ijo.2014.2576","volume":"45","author":"A Asmarinah","year":"2014","unstructured":"Asmarinah A, et al. Expression of the Bcl-2 family genes and complexes involved in the mitochondrial transport in prostate cancer cells. Int J Oncol. 2014;45(4):1489\u201396.","journal-title":"Int J Oncol"},{"issue":"14","key":"2594_CR10","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1002\/pros.22857","volume":"74","author":"A Calastretti","year":"2014","unstructured":"Calastretti A, et al. Down-modulation of Bcl-2 sensitizes PTEN-mutated prostate cancer cells to starvation and taxanes. Prostate. 2014;74(14):1411\u201322.","journal-title":"Prostate"},{"issue":"6","key":"2594_CR11","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.ajpath.2012.08.011","volume":"181","author":"M Puhr","year":"2012","unstructured":"Puhr M, et al. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol. 2012;181(6):2188\u2013201.","journal-title":"Am J Pathol"},{"issue":"8","key":"2594_CR12","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1158\/0008-5472.CAN-19-3466","volume":"80","author":"MS Roberts","year":"2020","unstructured":"Roberts MS, et al. LIN9 and NEK2 are core regulators of mitotic fidelity that can be therapeutically targeted to overcome taxane resistance. Cancer Res. 2020;80(8):1693\u2013706.","journal-title":"Cancer Res"},{"issue":"3","key":"2594_CR13","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3892\/or.2014.3290","volume":"43","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, et al. Downregulation of GPSM2 is associated with primary resistance to Paclitaxel in breast cancer. Oncol Rep. 2020;43(3):965\u201374.","journal-title":"Oncol Rep"},{"issue":"6","key":"2594_CR14","first-page":"423","volume":"19","author":"E Kopczynska","year":"2015","unstructured":"Kopczynska E. Role of MicroRNAs in the resistance of prostate cancer to docetaxel and Paclitaxel. Contemp Oncol (Pozn). 2015;19(6):423\u20137.","journal-title":"Contemp Oncol (Pozn)"},{"issue":"1","key":"2594_CR15","doi-asserted-by":"publisher","first-page":"4684","DOI":"10.1038\/s41467-020-18504-7","volume":"11","author":"N Gremke","year":"2020","unstructured":"Gremke N, et al. mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability. Nat Commun. 2020;11(1):4684.","journal-title":"Nat Commun"},{"issue":"11","key":"2594_CR16","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.trecan.2016.10.006","volume":"2","author":"Y Guri","year":"2016","unstructured":"Guri Y, Hall MN. mTOR signaling confers resistance to targeted cancer drugs. Trends Cancer. 2016;2(11):688\u201397.","journal-title":"Trends Cancer"},{"issue":"5","key":"2594_CR17","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.trecan.2016.03.008","volume":"2","author":"E Ilagan","year":"2016","unstructured":"Ilagan E, Manning BD. Emerging role of mTOR in the response to cancer therapeutics. Trends Cancer. 2016;2(5):241\u201351.","journal-title":"Trends Cancer"},{"issue":"20","key":"2594_CR18","doi-asserted-by":"publisher","first-page":"8809","DOI":"10.1128\/MCB.25.20.8809-8823.2005","volume":"25","author":"A Panner","year":"2005","unstructured":"Panner A, et al. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol. 2005;25(20):8809\u201323.","journal-title":"Mol Cell Biol"},{"issue":"11","key":"2594_CR19","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1158\/1541-7786.MCR-05-0063","volume":"3","author":"DJ Vanderweele","year":"2005","unstructured":"Vanderweele DJ, Rudin CM. Mammalian target of Rapamycin promotes vincristine resistance through multiple mechanisms independent of maintained glycolytic rate. Mol Cancer Res. 2005;3(11):635\u201344.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"2594_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","volume":"12","author":"DA Guertin","year":"2007","unstructured":"Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12(1):9\u201322.","journal-title":"Cancer Cell"},{"key":"2594_CR21","doi-asserted-by":"crossref","unstructured":"Tian T, Li X, Zhang J. mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy. Int J Mol Sci. 2019;20(3):755.","DOI":"10.3390\/ijms20030755"},{"issue":"8","key":"2594_CR22","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nrd2062","volume":"5","author":"S Faivre","year":"2006","unstructured":"Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006;5(8):671\u201388.","journal-title":"Nat Rev Drug Discov"},{"key":"2594_CR23","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.semcancer.2019.07.003","volume":"59","author":"AK Murugan","year":"2019","unstructured":"Murugan AK. mTOR: role in cancer, metastasis and drug resistance. Semin Cancer Biol. 2019;59:92\u2013111.","journal-title":"Semin Cancer Biol"},{"key":"2594_CR24","doi-asserted-by":"crossref","unstructured":"Adhikari S, et al. The paradigm of drug resistance in cancer: an epigenetic perspective. Biosci Rep. 2022;42(4):BSR20211812.","DOI":"10.1042\/BSR20211812"},{"issue":"2","key":"2594_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-019-0267-4","volume":"17","author":"D Morel","year":"2020","unstructured":"Morel D, et al. Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise. Nat Rev Clin Oncol. 2020;17(2):91\u2013107.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"2594_CR26","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2217\/epi-2023-0142","volume":"15","author":"D Singh","year":"2023","unstructured":"Singh D, Khan MA, Siddique HR. Role of epigenetic drugs in sensitizing cancers to anticancer therapies: emerging trends and clinical advancements. Epigenomics. 2023;15(8):517\u201337.","journal-title":"Epigenomics"},{"issue":"21","key":"2594_CR27","doi-asserted-by":"publisher","first-page":"8726","DOI":"10.1158\/0008-5472.CAN-10-0755","volume":"70","author":"H Huo","year":"2010","unstructured":"Huo H, et al. Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance. Cancer Res. 2010;70(21):8726\u201335.","journal-title":"Cancer Res"},{"issue":"6","key":"2594_CR28","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1016\/j.gendis.2023.01.034","volume":"10","author":"G Li","year":"2023","unstructured":"Li G, et al. Development of a dual targeting scaffold of SET7\/MLL inhibitor for castration-resistant prostate cancer treatment. Genes Dis. 2023;10(6):2260\u20132.","journal-title":"Genes Dis"},{"issue":"4","key":"2594_CR29","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/nm.3830","volume":"21","author":"R Malik","year":"2015","unstructured":"Malik R, et al. Targeting the MLL complex in castration-resistant prostate cancer. Nat Med. 2015;21(4):344\u201352.","journal-title":"Nat Med"},{"key":"2594_CR30","doi-asserted-by":"crossref","unstructured":"Yang L, Jin ML, Jeong KW. Histone H3K4 methyltransferases as targets for Drug-Resistant cancers. Biol Basel. 2021;10(7):581.","DOI":"10.3390\/biology10070581"},{"issue":"4","key":"2594_CR31","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.jhep.2014.05.015","volume":"61","author":"SB Gao","year":"2014","unstructured":"Gao SB, et al. The functional and mechanistic relatedness of EZH2 and Menin in hepatocellular carcinoma. J Hepatol. 2014;61(4):832\u20139.","journal-title":"J Hepatol"},{"issue":"12","key":"2594_CR32","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/cac2.12217","volume":"41","author":"Y Luo","year":"2021","unstructured":"Luo Y, et al. The scaffold protein Menin is essential for activating the MYC locus and MYC-mediated androgen receptor transcription in androgen receptor-dependent prostate cancer cells. Cancer Commun (Lond). 2021;41(12):1427\u201330.","journal-title":"Cancer Commun (Lond)"},{"issue":"43","key":"2594_CR33","doi-asserted-by":"publisher","first-page":"17480","DOI":"10.1073\/pnas.1312022110","volume":"110","author":"B Xu","year":"2013","unstructured":"Xu B, et al. Menin promotes hepatocellular carcinogenesis and epigenetically up-regulates Yap1 transcription. Proc Natl Acad Sci U S A. 2013;110(43):17480\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2594_CR34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ccr.2008.05.003","volume":"14","author":"A Yokoyama","year":"2008","unstructured":"Yokoyama A, Cleary ML. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell. 2008;14(1):36\u201346.","journal-title":"Cancer Cell"},{"issue":"2","key":"2594_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","volume":"123","author":"A Yokoyama","year":"2005","unstructured":"Yokoyama A, et al. The Menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell. 2005;123(2):207\u201318.","journal-title":"Cell"},{"issue":"1","key":"2594_CR36","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41388-021-02039-2","volume":"41","author":"C Cherif","year":"2022","unstructured":"Cherif C, et al. Menin Inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity. Oncogene. 2022;41(1):125\u201337.","journal-title":"Oncogene"},{"issue":"4","key":"2594_CR37","doi-asserted-by":"publisher","first-page":"202","DOI":"10.14348\/molcells.2021.0206","volume":"45","author":"T Kim","year":"2022","unstructured":"Kim T, et al. Menin enhances androgen Receptor-Independent proliferation and migration of prostate cancer cells. Mol Cells. 2022;45(4):202\u201315.","journal-title":"Mol Cells"},{"issue":"3suppl","key":"2594_CR38","doi-asserted-by":"publisher","first-page":"TPS716","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS716","volume":"42","author":"C Fountzilas","year":"2024","unstructured":"Fountzilas C, et al. COVALENT-102: A phase 1\/1b dose finding study of BMF-219, an oral covalent Menin inhibitor, in adults with locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC), pancreatic cancer (PDAC) and colorectal cancer (CRC) with activating KRAS mutations. J Clin Oncol. 2024;42(3suppl):TPS716\u2013716.","journal-title":"J Clin Oncol"},{"key":"2594_CR39","unstructured":"Issa GC, et al. Menin Inhibition with revumenib for KMT2A-Rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol. 2024;JCO2400826.43(1):75\u201384."},{"key":"2594_CR40","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13072-015-0014-8","volume":"8","author":"A Diez-Villanueva","year":"2015","unstructured":"Diez-Villanueva A, Mallona I, Peinado MA. Wanderer, an interactive viewer to explore DNA methylation and gene expression data in human cancer. Epigenetics Chromatin. 2015;8:22.","journal-title":"Epigenetics Chromatin"},{"issue":"5","key":"2594_CR41","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134.","journal-title":"Cancer Discov"},{"issue":"2","key":"2594_CR42","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","volume":"162","author":"D Robinson","year":"2015","unstructured":"Robinson D, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;162(2):454.","journal-title":"Cell"},{"key":"2594_CR43","doi-asserted-by":"crossref","unstructured":"Jiang J, et al. CTR-DB 2.0: an updated cancer clinical transcriptome resource, expanding primary drug resistance and newly adding acquired resistance datasets and enhancing the discovery and validation of predictive biomarkers. Nucleic Acids Research. 2025;53(D1):D1335\u201347.","DOI":"10.1093\/nar\/gkae993"},{"issue":"7","key":"2594_CR44","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750\u201367.","journal-title":"J Clin Invest"},{"key":"2594_CR45","unstructured":"Benchling [Biology Software]. Accessed: 15 July 2024. Available from: https:\/\/benchling.com"},{"issue":"11","key":"2594_CR46","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, et al. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8(11):2281\u2013308.","journal-title":"Nat Protoc"},{"key":"2594_CR47","unstructured":"SRPlot. Available from: https:\/\/www.bioinformatics.com.cn\/en.\u00a0Accessed: 10 July 2024."},{"key":"2594_CR48","unstructured":"Eukaryotic Promoter. DataBase. Available from: https:\/\/epd.expasy.org\/epd\/.\u00a0Accessed: 20 June 2024."},{"key":"2594_CR49","unstructured":"NCBI. Primer Designing Tool. Accessed: 10 June 2024. Available from: https:\/\/www.ncbi.nlm.nih.gov\/tools\/primer-blast\/"},{"issue":"2","key":"2594_CR50","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/(SICI)1097-0320(19991001)37:2<113::AID-CYTO4>3.0.CO;2-M","volume":"37","author":"G Sena","year":"1999","unstructured":"Sena G, et al. Measuring the complexity of cell cycle arrest and killing of drugs: kinetics of phase-specific effects induced by taxol. Cytometry. 1999;37(2):113\u201324.","journal-title":"Cytometry"},{"issue":"2","key":"2594_CR51","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1182\/blood-2002-06-1785","volume":"101","author":"CW So","year":"2003","unstructured":"So CW, Cleary ML. Common mechanism for oncogenic activation of MLL by forkhead family proteins. Blood. 2003;101(2):633\u20139.","journal-title":"Blood"},{"issue":"50","key":"2594_CR52","doi-asserted-by":"publisher","first-page":"25260","DOI":"10.1073\/pnas.1910391116","volume":"116","author":"LR Thomas","year":"2019","unstructured":"Thomas LR, et al. Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance. Proc Natl Acad Sci U S A. 2019;116(50):25260\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2594_CR53","doi-asserted-by":"publisher","first-page":"10194","DOI":"10.18632\/aging.103377","volume":"12","author":"WH Chappell","year":"2020","unstructured":"Chappell WH, et al. Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf\/MEK\/ERK and PI3K\/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines. Aging. 2020;12(11):10194\u2013210.","journal-title":"Aging"},{"key":"2594_CR54","unstructured":"ChIP Atlas Study, Study ID: SRX11712604. Available from: https:\/\/chip-atlas.org\/view?id=SRX11712604.\u00a0Accessed: 01 June 2024."},{"key":"2594_CR55","unstructured":"ChIP Atlas Study, Study ID: SRX14030471. Available from:\u00a0https:\/\/chip-atlas.org\/view?id=SRX14030471.\u00a0Accessed: 01 June 2024."},{"key":"2594_CR56","unstructured":"ChIP Atlas Study, Study ID: SRX4046307. Accessed: 01 June 2024. Available from: https:\/\/chip-atlas.org\/view?id=SRX4046307"},{"key":"2594_CR57","unstructured":"ChIP Atlas Study, Study ID: SRX14030482. Available from: https:\/\/chip-atlas.org\/view?id=SRX14030482.\u00a0Accessed: 01 June 2024."},{"key":"2594_CR58","unstructured":"ChIP Atlas Study, Study ID: SRX11712606. Available from: https:\/\/chip-atlas.org\/view?id=SRX11712606.\u00a0Accessed: 01 June 2024."},{"issue":"3","key":"2594_CR59","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ccell.2016.02.006","volume":"29","author":"S Goel","year":"2016","unstructured":"Goel S, et al. Overcoming therapeutic resistance in HER2-Positive breast cancers with CDK4\/6 inhibitors. Cancer Cell. 2016;29(3):255\u201369.","journal-title":"Cancer Cell"},{"issue":"13","key":"2594_CR60","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1158\/1078-0432.CCR-14-0816","volume":"21","author":"T VanArsdale","year":"2015","unstructured":"VanArsdale T, et al. Molecular pathways: targeting the Cyclin D-CDK4\/6 axis for cancer treatment. Clin Cancer Res. 2015;21(13):2905\u201310.","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2594_CR61","doi-asserted-by":"publisher","first-page":"12483","DOI":"10.1093\/nar\/gkaa1002","volume":"48","author":"S Hume","year":"2020","unstructured":"Hume S, Dianov GL, Ramadan K. A unified model for the G1\/S cell cycle transition. Nucleic Acids Res. 2020;48(22):12483\u2013501.","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"2594_CR62","first-page":"3635","volume":"9","author":"JI Daksis","year":"1994","unstructured":"Daksis JI, et al. Myc induces Cyclin D1 expression in the absence of de Novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. Oncogene. 1994;9(12):3635\u201345.","journal-title":"Oncogene"},{"key":"2594_CR63","doi-asserted-by":"publisher","first-page":"15278","DOI":"10.1038\/ncomms15278","volume":"8","author":"G Wu","year":"2017","unstructured":"Wu G, et al. Menin enhances c-Myc-mediated transcription to promote cancer progression. Nat Commun. 2017;8:15278.","journal-title":"Nat Commun"},{"issue":"12","key":"2594_CR64","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/jnci\/djm011","volume":"99","author":"SS Ng","year":"2007","unstructured":"Ng SS, et al. Cell cycle-related kinase: a novel candidate oncogene in human glioblastoma. J Natl Cancer Inst. 2007;99(12):936\u201348.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2594_CR65","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3892\/ol.2012.828","volume":"4","author":"Y Tian","year":"2012","unstructured":"Tian Y, Wan H, Tan G. Cell cycle-related kinase in carcinogenesis. Oncol Lett. 2012;4(4):601\u20136.","journal-title":"Oncol Lett"},{"issue":"11","key":"2594_CR66","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1002\/ijc.24630","volume":"125","author":"GQ Wu","year":"2009","unstructured":"Wu GQ, et al. Cell cycle-related kinase supports ovarian carcinoma cell proliferation via regulation of Cyclin D1 and is a predictor of outcome in patients with ovarian carcinoma. Int J Cancer. 2009;125(11):2631\u201342.","journal-title":"Int J Cancer"},{"issue":"3","key":"2594_CR67","doi-asserted-by":"publisher","first-page":"339","DOI":"10.15171\/apb.2017.041","volume":"7","author":"B Mansoori","year":"2017","unstructured":"Mansoori B, et al. The different mechanisms of cancer drug resistance: A brief review. Adv Pharm Bull. 2017;7(3):339\u201348.","journal-title":"Adv Pharm Bull"},{"issue":"1","key":"2594_CR68","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41420-024-01803-z","volume":"10","author":"X Yu","year":"2024","unstructured":"Yu X, et al. Cancer epigenetics: from laboratory studies and clinical trials to precision medicine. Cell Death Discov. 2024;10(1):28.","journal-title":"Cell Death Discov"},{"key":"2594_CR69","doi-asserted-by":"crossref","unstructured":"Daver N, et al. Phase 1\/2 First-in-Human study of the Menin-MLL inhibitor DSP-5336 in patients with relapsed or refractory acute leukemia. Blood. 2023;142:2911 .","DOI":"10.1182\/blood-2023-179252"},{"issue":"3","key":"2594_CR70","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nchembio.773","volume":"8","author":"J Grembecka","year":"2012","unstructured":"Grembecka J, et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol. 2012;8(3):277\u201384.","journal-title":"Nat Chem Biol"},{"issue":"21","key":"2594_CR71","doi-asserted-by":"publisher","first-page":"15519","DOI":"10.1021\/acs.jmedchem.1c00872","volume":"64","author":"H Lei","year":"2021","unstructured":"Lei H, et al. Recent progress of small molecule Menin-MLL interaction inhibitors as therapeutic agents for acute leukemia. J Med Chem. 2021;64(21):15519\u201333.","journal-title":"J Med Chem"},{"issue":"1","key":"2594_CR72","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13148-019-0723-0","volume":"11","author":"J Ye","year":"2019","unstructured":"Ye J, et al. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair. Clin Epigenetics. 2019;11(1):137.","journal-title":"Clin Epigenetics"},{"issue":"5311","key":"2594_CR73","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1126\/science.276.5311.404","volume":"276","author":"SC Chandrasekharappa","year":"1997","unstructured":"Chandrasekharappa SC, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997;276(5311):404\u20137.","journal-title":"Science"},{"issue":"1","key":"2594_CR74","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1038\/s41467-018-05854-6","volume":"9","author":"J Suzuki","year":"2018","unstructured":"Suzuki J, et al. The tumor suppressor Menin prevents effector CD8 T-cell dysfunction by targeting mTORC1-dependent metabolic activation. Nat Commun. 2018;9(1):3296.","journal-title":"Nat Commun"},{"key":"2594_CR75","doi-asserted-by":"crossref","unstructured":"Braun KA, et al. Menin drives oncogenesis in ewing sarcoma cells by activating transcription of key metastatic factors. Cancer Res. 2024;84(6):6601-6601 .","DOI":"10.1158\/1538-7445.AM2024-6601"},{"issue":"10","key":"2594_CR76","doi-asserted-by":"publisher","first-page":"T135","DOI":"10.1530\/ERC-17-0281","volume":"24","author":"KMA Dreijerink","year":"2017","unstructured":"Dreijerink KMA, Timmers HTM, Brown M. Twenty years of menin: emerging opportunities for restoration of transcriptional regulation in MEN1. Endocr Relat Cancer. 2017;24(10):T135\u201345.","journal-title":"Endocr Relat Cancer"},{"issue":"7\u20138","key":"2594_CR77","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41417-019-0127-5","volume":"27","author":"ZF Wang","year":"2020","unstructured":"Wang ZF, et al. Abnormal expression of Menin predicts the pathogenesis and poor prognosis of adult gliomas. Cancer Gene Ther. 2020;27(7\u20138):539\u201347.","journal-title":"Cancer Gene Ther"},{"issue":"10","key":"2594_CR78","doi-asserted-by":"publisher","first-page":"T147","DOI":"10.1530\/ERC-17-0298","volume":"24","author":"Z Feng","year":"2017","unstructured":"Feng Z, Ma J, Hua X. Epigenetic regulation by the Menin pathway. Endocr Relat Cancer. 2017;24(10):T147\u201359.","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"2594_CR79","doi-asserted-by":"publisher","first-page":"R83","DOI":"10.1530\/ERC-12-0394","volume":"20","author":"RL Bitting","year":"2013","unstructured":"Bitting RL, Armstrong AJ. Targeting the PI3K\/Akt\/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer. 2013;20(3):R83\u201399.","journal-title":"Endocr Relat Cancer"},{"key":"2594_CR80","doi-asserted-by":"publisher","first-page":"628690","DOI":"10.3389\/fphar.2021.628690","volume":"12","author":"C Dong","year":"2021","unstructured":"Dong C, et al. Activation of PI3K\/AKT\/mTOR pathway causes drug resistance in breast cancer. Front Pharmacol. 2021;12:628690.","journal-title":"Front Pharmacol"},{"issue":"3","key":"2594_CR81","doi-asserted-by":"publisher","first-page":"378","DOI":"10.4103\/1008-682X.122876","volume":"16","author":"MP Edlind","year":"2014","unstructured":"Edlind MP, Hsieh AC. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl. 2014;16(3):378\u201386.","journal-title":"Asian J Androl"},{"key":"2594_CR82","doi-asserted-by":"crossref","unstructured":"Faruq O, et al. Targeting an MDM2\/MYC axis to overcome drug resistance in multiple myeloma. Cancers (Basel). 2022;14(6):1592.","DOI":"10.3390\/cancers14061592"},{"issue":"3","key":"2594_CR83","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.drup.2008.03.001","volume":"11","author":"BH Jiang","year":"2008","unstructured":"Jiang BH, Liu LZ. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat. 2008;11(3):63\u201376.","journal-title":"Drug Resist Updat"},{"key":"2594_CR84","doi-asserted-by":"crossref","unstructured":"Pungsrinont T, Kallenbach J, Baniahmad A. Role of PI3K-AKT-mTOR pathway as a Pro-Survival signaling and Resistance-Mediating mechanism to therapy of prostate cancer. Int J Mol Sci. 2021;22(20):11088.","DOI":"10.3390\/ijms222011088"},{"issue":"1","key":"2594_CR85","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.leukres.2014.11.004","volume":"39","author":"B Xia","year":"2015","unstructured":"Xia B, et al. c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia. Leuk Res. 2015;39(1):92\u20139.","journal-title":"Leuk Res"},{"issue":"12","key":"2594_CR86","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1111\/apm.12296","volume":"122","author":"C Xie","year":"2014","unstructured":"Xie C, et al. C-Myc participates in beta-catenin-mediated drug resistance in A549\/DDP lung adenocarcinoma cells. APMIS. 2014;122(12):1251\u20138.","journal-title":"APMIS"},{"issue":"4","key":"2594_CR87","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.clgc.2013.05.007","volume":"11","author":"AJ Armstrong","year":"2013","unstructured":"Armstrong AJ, et al. A phase II trial of Temsirolimus in men with castration-resistant metastatic prostate cancer. Clin Genitourin Cancer. 2013;11(4):397\u2013406.","journal-title":"Clin Genitourin Cancer"},{"issue":"7015","key":"2594_CR88","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature03094","volume":"432","author":"J Massague","year":"2004","unstructured":"Massague J. G1 cell-cycle control and cancer. Nature. 2004;432(7015):298\u2013306.","journal-title":"Nature"},{"key":"2594_CR89","doi-asserted-by":"crossref","unstructured":"Montalto FI, De Amicis F. Cyclin D1 in cancer: a molecular connection for cell cycle Control, adhesion and invasion in tumor and stroma. Cells. 2020;9(12):2648.","DOI":"10.3390\/cells9122648"},{"issue":"5","key":"2594_CR90","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.jhep.2014.11.040","volume":"62","author":"H Feng","year":"2015","unstructured":"Feng H, et al. A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients. J Hepatol. 2015;62(5):1100\u201311.","journal-title":"J Hepatol"},{"issue":"8","key":"2594_CR91","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/embor.2013.80","volume":"14","author":"Y Yang","year":"2013","unstructured":"Yang Y, Roine N, Makela TP. CCRK depletion inhibits glioblastoma cell proliferation in a cilium-dependent manner. EMBO Rep. 2013;14(8):741\u20137.","journal-title":"EMBO Rep"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02594-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-025-02594-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02594-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T10:07:00Z","timestamp":1769681220000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-025-02594-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2594"],"URL":"https:\/\/doi.org\/10.1186\/s12964-025-02594-1","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Koc University Local Ethics Committee approved animal experiments for Animal Experiments (HADYEK) with the protocol number 2022.HADYEK.030. No human subjects were included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"66"}}